Drug Profile
DMPDDF
Latest Information Update: 02 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline; University of South Alabama
- Developer GSK; University of South Alabama
- Class Antineoplastics; Small molecules
- Mechanism of Action Thymidylate synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 21 Jan 2005 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 06 Dec 2000 Profile reviewed but no significant changes made
- 30 Oct 1997 No-Development-Reported for Cancer in USA (Unknown route)